Description
Ionis Pharmaceuticals, Inc.: Initiation Of Coverage – Its New wholly-owned medicines and Independent launches Can Catalyze Growth?
Ionis Pharmaceuticals Inc. had a remarkable year in 2023, with significant advancements in their RNA[1]targeting platform and a steady stream of upcoming independent medicines delivering directly to patients. The company’s forward-looking stratagem involves expanding their technology and broadening its applicability to cater to patients’ needs.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures
Want unlimited access to our reports? Purchase our $99 annual subscription!
